new
   What Are the Side Effects of Rasagiline (Azilect)?
508
Nov 13, 2025

Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, approved for the treatment of Parkinson's disease. While this medication effectively improves motor symptoms, a series of potential side effect risks are associated with its efficacy.

What Are the Side Effects of Rasagiline (Azilect)?

Common Reactions in Monotherapy

Influenza-like symptoms (5%).

Arthralgia (7%).

Dyspepsia (7%).

Depression (5%).

Headache (14%).

Falls (5%).

Side Effects in Adjunctive Therapy Without Levodopa

Peripheral edema (7%).

Falls (6%).

Cough (4%).

Side Effects in Adjunctive Therapy With Levodopa

Dyskinesia (18%).

Accidental injuries (12%).

Weight loss (9%).

Warnings for Severe Side Effects of Rasagiline (Azilect).

Risk of Hypertension

May exacerbate hypertension; new-onset hypertension or poorly controlled blood pressure should be monitored.

When used in combination with levodopa, the incidence of significant blood pressure elevation (systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg) is 4%.

Although routine dietary tyramine restriction is not required, consumption of foods containing extremely high amounts of tyramine (> 150 mg) should be avoided.

Serotonin Syndrome

High-risk contraindicated concomitant medications: meperidine, tramadol, methadone, dextromethorphan.

Other MAO inhibitors (including selective MAO-B inhibitors).

St. John's wort, cyclobenzaprine.

Other Severe Neurological Reactions

Dyskinesia.

Hallucinations/psychotic-like behaviors.

Impulse control/compulsive behaviors.

Withdrawal-related hyperpyrexia and confusion.

Precautions for Using Rasagiline (Azilect)

Individualized Dosing Regimen

Monotherapy: 1 mg once daily.

Adjunctive therapy without levodopa: 1 mg once daily.

Adjunctive therapy with levodopa: Initial dose of 0.5 mg once daily, which may be increased to 1 mg once daily.

Dosage Adjustments for Special Populations

Patients taking ciprofloxacin or other CYP1A2 inhibitors: Do not exceed 0.5 mg once daily.

Mild hepatic impairment: Do not exceed 0.5 mg once daily.

Moderate or severe hepatic impairment: Contraindicated.

Lifestyle Management

Driving warning: Avoid driving if somnolence occurs.

Dietary advice: Avoid large amounts of tyramine-containing foods (e.g., aged cheese).

Symptom Reporting Mechanism

Recognize symptoms of hepatotoxicity: unusual fatigue, abdominal pain, jaundice.

Report new or worsening psychiatric symptoms: hallucinations, abnormal impulses, etc.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Storage Conditions for Risdiplam Tablets (Evrysdi)

Proper storage methods ensure the stability and efficacy of the medication.

I. Storage requirements for oral...

Tuesday, June 9th, 2026, 17:35
Pacritinib (Vonjo) Precautions for Administration

Pacritinib is a JAK2/FLT3 inhibitor used for the treatment of splenomegaly or symptoms associated with...

Tuesday, June 9th, 2026, 09:32
Indications and Contraindications of Ruzabrutinib (Wayrilz)

Rezabrutinib is a highly selective BTK inhibitor indicated for various B-cell hematologic malignancies.

I....

Friday, June 5th, 2026, 11:53
Use in Special Populations for Rezabrutinib (Wayrilz)

Patients in different physiological and pathological states have differences in drug metabolism and tolerance....

Friday, June 5th, 2026, 09:54
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved